

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): April 2, 2020

BioCryst Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of Incorporation)

000-23186
(Commission File Number)

62-1413174
(I.R.S. Employer Identification Number)

4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703
(Address of Principal Executive Offices) (Zip Code)

(919) 859-1302
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	BCRX	Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 2, 2020, BioCryst Pharmaceuticals, Inc. (the “Company”) announced that the Company has appointed Anthony Doyle to the position of Senior Vice President & Chief Financial Officer.

Mr. Doyle, 40, joins the Company from Worldwide Clinical Trials Holdings, Inc. (“WCT”), a full service global contract research organization, where he served as Chief Financial Officer since 2014. From 2004 to 2012, Mr. Doyle held a series of increasingly responsible roles at General Electric, moving through financial planning & analysis, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs. He then led risk and pricing for GE Healthcare’s \$1.2 billion U.S. diagnostic imaging business and served as global program manager for GE Healthcare Solutions, a hospital and healthcare outcomes-based consulting company. From 2012 to 2014, he was CFO of World Book, a Berkshire Hathaway company.

Mr. Doyle completed his Bachelor’s degree from Dublin City University (Ireland) and his DESEM from Reims Management School (France). Mr. Doyle also has a Graduate Certificate in Corporate Treasury from Dublin City University.

Mr. Doyle will receive a base salary of \$480,000 annually, with a target percentage under the Company’s Annual Incentive Plan (“AIP”) of 40% of base salary and a maximum percentage under the AIP of 48% of base salary. Mr. Doyle’s AIP payout for 2020 performance will not be prorated based on his start date. Mr. Doyle will also receive a \$50,000 signing bonus payable on or before the six month anniversary of his start date. In addition, on April 30, 2020, pursuant to the Company’s Inducement Equity Incentive Plan and Stock Incentive Plan, the Compensation Committee of the Company’s Board of Directors will grant to Mr. Doyle options to purchase 600,000 shares of the Company’s common stock, 200,000 of which will vest on the first anniversary of the grant or upon termination if, within the first year of his employment, Mr. Doyle is impacted by a reduction in force at the Company, and the remainder of which will vest in three equal annual installments, beginning on the second anniversary of his start date.

Mr. Doyle does not have a family relationship with any of the Company’s officers or directors and has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Item 7.01. Regulation FD Disclosure.

On April 2, 2020, the Company issued a news release announcing the events described in Item 5.02 of this Current Report on Form 8-K. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference into this Item 7.01.

The information furnished is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, is not subject to the liabilities of that section and is not deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
<u>99.1</u>	<u>Press Release dated April 2, 2020 entitled “BioCryst Appoints Anthony Doyle Chief Financial Officer.”</u>

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioCryst Pharmaceuticals, Inc.

Date: April 2, 2020

By: /s/ Alane Barnes

Alane Barnes

Senior Vice President and Chief Legal Officer

BioCryst Appoints Anthony Doyle Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C., April 02, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Anthony Doyle as senior vice president and chief financial officer (CFO).

Mr. Doyle joins BioCryst from Worldwide Clinical Trials, a full-service global contract research organization, where he has served as CFO since 2014.

From 2004 to 2012, Mr. Doyle held a series of increasingly responsible roles at General Electric (GE), moving through FP&A, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate Audit Staff finance and leadership training programs. He then led risk and pricing for GE Healthcare's \$1.2 billion U.S. diagnostic imaging business and served as global program manager for GE Healthcare Solutions, a hospital and healthcare outcomes-based consulting company. From 2012 to 2014, he was CFO of World Book, a Berkshire Hathaway company.

"Anthony is a seasoned, global, life science leader who brings a track record of accomplishment helping build and grow businesses. This is exactly what we need as we prepare for our first launch with berotralstat and advance our very exciting pipeline," said Jon Stonehouse, chief executive officer of BioCryst.

"BioCryst is a uniquely positioned biotech company with significant potential near-term revenues and a dynamic pipeline right behind it. I am excited to add my experience to the team as the company accelerates through its commercial transition and delivers important new oral medicines to patients with rare diseases," Doyle said.

Mr. Doyle received his B.A. from Dublin City University (Ireland) and his DESEM from Reims Management School (France).

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing development programs including berotralstat (BCX7353), an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for Marburg virus disease and Yellow Fever, and BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include: that developing any HAE product candidate may take longer or may be more expensive than planned; that ongoing and future preclinical and clinical studies may not have positive results; that BioCryst may not be able to enroll the required number of subjects in planned clinical trials of product candidates; that BioCryst may not advance human clinical trials with product candidates as expected; that the FDA, EMA, PMDA or other applicable regulatory agency decisions or processes may be negatively impacted by the COVID-19 pandemic; that such agencies may require additional studies beyond the studies planned for product candidates, or may not provide regulatory clearances which may result in delay of planned clinical trials, or may impose a clinical hold with respect to such product candidates, or withhold market approval for product candidates; that actual financial results may not be consistent with expectations, including that 2020 operating expenses and cash usage may not be within management's expected ranges. Please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst's most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, all of which identify important factors that could cause the actual results to differ materially from those contained in BioCryst's projections and forward-looking statements.

BCRXW

Contact:

John Bluth
+1 919 859 7910
jbluth@biocryst.com